JP7094950B2 - 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 - Google Patents

抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 Download PDF

Info

Publication number
JP7094950B2
JP7094950B2 JP2019522273A JP2019522273A JP7094950B2 JP 7094950 B2 JP7094950 B2 JP 7094950B2 JP 2019522273 A JP2019522273 A JP 2019522273A JP 2019522273 A JP2019522273 A JP 2019522273A JP 7094950 B2 JP7094950 B2 JP 7094950B2
Authority
JP
Japan
Prior art keywords
lymphoma
sequence
hodgkin
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533682A5 (enExample
JP2019533682A (ja
Inventor
エンデル，ヤン
ペトロプーロス，コンスタンティン
ケレメン，ペーター
ボクスハマー，ライナー
リュケルト，マルクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2019533682A publication Critical patent/JP2019533682A/ja
Publication of JP2019533682A5 publication Critical patent/JP2019533682A5/ja
Priority to JP2022100006A priority Critical patent/JP2022137089A/ja
Application granted granted Critical
Publication of JP7094950B2 publication Critical patent/JP7094950B2/ja
Priority to JP2024125584A priority patent/JP2024167208A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019522273A 2016-10-28 2017-10-27 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 Active JP7094950B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100006A JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196184.2 2016-10-28
EP16196184 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100006A Division JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Publications (3)

Publication Number Publication Date
JP2019533682A JP2019533682A (ja) 2019-11-21
JP2019533682A5 JP2019533682A5 (enExample) 2020-12-03
JP7094950B2 true JP7094950B2 (ja) 2022-07-04

Family

ID=57218739

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019522273A Active JP7094950B2 (ja) 2016-10-28 2017-10-27 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2022100006A Pending JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A Pending JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100006A Pending JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A Pending JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Country Status (26)

Country Link
US (1) US12358983B2 (enExample)
EP (2) EP3903821A1 (enExample)
JP (3) JP7094950B2 (enExample)
KR (2) KR20230028571A (enExample)
CN (2) CN118045175A (enExample)
AU (2) AU2017348624B2 (enExample)
BR (1) BR112019008244A2 (enExample)
CA (1) CA3037246A1 (enExample)
CY (1) CY1124648T1 (enExample)
DK (1) DK3532098T3 (enExample)
ES (1) ES2871574T3 (enExample)
HR (1) HRP20210838T1 (enExample)
HU (1) HUE054496T2 (enExample)
IL (3) IL266216B2 (enExample)
LT (1) LT3532098T (enExample)
MX (2) MX2019004942A (enExample)
NZ (1) NZ751414A (enExample)
PL (1) PL3532098T3 (enExample)
PT (1) PT3532098T (enExample)
RS (1) RS62036B1 (enExample)
RU (1) RU2756405C2 (enExample)
SG (1) SG10202104036QA (enExample)
SI (1) SI3532098T1 (enExample)
SM (1) SMT202100347T1 (enExample)
WO (1) WO2018078123A1 (enExample)
ZA (1) ZA201903302B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
JP7590083B2 (ja) * 2018-08-31 2024-11-26 アーデーセー セラピューティクス ソシエテ アノニム 併用療法
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
AU2020375149A1 (en) * 2019-10-31 2022-05-12 Incyte Corporation Sequential anti-CD19 therapy
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
JP5825756B2 (ja) 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
BRPI0716661B1 (pt) 2006-08-15 2019-05-21 Hydralift Amclyde, Inc. Aparelho e método para prover compensação de levantamento para uma carga suspensa de uma extremidade de um cabo em um ambiente marinho, com a outra extremidade do cabo.
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US8543911B2 (en) 2011-01-18 2013-09-24 Apple Inc. Ordering document content based on reading flow
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP3077384B1 (en) * 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
SI3888674T1 (sl) * 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
AU2015277516A1 (en) 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
EP3209690B1 (en) 2014-10-20 2021-05-05 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
CA2972827A1 (en) * 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine
MX389342B (es) 2015-05-26 2025-03-20 Hoffmann La Roche Un anticuerpo anti-cd20 en combinación con un inhibidor de bcl-2 y un inhibidor de mdm2 para usarse en el tratamiento de cáncer.
PL3302550T3 (pl) 2015-05-26 2020-02-28 Morphosys Ag Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania
EP3316888A1 (en) 2015-07-02 2018-05-09 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
SG11201810159TA (en) 2016-05-30 2018-12-28 Morphosys Ag Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
AU2020375149A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Sequential anti-CD19 therapy
TWI883067B (zh) 2019-10-31 2025-05-11 美商英塞特公司 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
JP7813225B2 (ja) 2019-10-31 2026-02-12 インサイト・コーポレイション 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法
CA3181827A1 (en) 2020-06-22 2021-12-30 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
CA3204063A1 (en) 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy
IL313736A (en) 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Seminars in Oncology，2016年04月01日，Vol. 43, No. 2, pp.280-290

Also Published As

Publication number Publication date
CY1124648T1 (el) 2022-07-22
RU2019113370A (ru) 2020-11-30
IL301786B2 (en) 2025-09-01
EP3903821A1 (en) 2021-11-03
AU2017348624B2 (en) 2024-09-26
CN109890418B (zh) 2024-03-08
BR112019008244A2 (pt) 2019-07-16
JP2024167208A (ja) 2024-12-03
RS62036B1 (sr) 2021-07-30
PL3532098T3 (pl) 2022-01-31
ZA201903302B (en) 2021-04-28
MX2019004942A (es) 2019-08-12
LT3532098T (lt) 2021-06-25
SG10202104036QA (en) 2021-05-28
CN109890418A (zh) 2019-06-14
AU2017348624A1 (en) 2019-03-28
IL301786A (en) 2023-05-01
IL266216B1 (en) 2023-05-01
IL301786B1 (en) 2025-05-01
ES2871574T3 (es) 2021-10-29
HRP20210838T1 (hr) 2021-08-06
WO2018078123A1 (en) 2018-05-03
KR102500868B1 (ko) 2023-02-16
DK3532098T3 (da) 2021-05-25
AU2024287178A1 (en) 2025-01-23
IL266216B2 (en) 2023-09-01
HUE054496T2 (hu) 2021-09-28
RU2756405C2 (ru) 2021-09-30
IL266216A (en) 2019-06-30
EP3532098B1 (en) 2021-04-07
NZ751414A (en) 2025-10-31
US12358983B2 (en) 2025-07-15
KR20190075942A (ko) 2019-07-01
RU2019113370A3 (enExample) 2021-03-01
EP3532098A1 (en) 2019-09-04
CN118045175A (zh) 2024-05-17
MX2022016270A (es) 2023-02-15
IL320372A (en) 2025-06-01
PT3532098T (pt) 2021-06-17
SMT202100347T1 (it) 2021-07-12
CA3037246A1 (en) 2018-05-03
SI3532098T1 (sl) 2021-12-31
KR20230028571A (ko) 2023-02-28
JP2019533682A (ja) 2019-11-21
US20190241656A1 (en) 2019-08-08
JP2022137089A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
JP7094950B2 (ja) 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40064491A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7094950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250